問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Radiation Therapy

Division of General Internal Medicine

Division of Thoracic Medicine

Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

更新時間:2023-09-19

林聖皓
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

59Cases

2025-04-01 - 2028-08-31

Phase I/II

Active
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors
  • Condition/Disease

    Squamous Non-small-cell Lung Cancer

  • Test Drug

    Infusion fluid

Participate Sites
4Sites

Recruiting4Sites

2025-06-18 - 2027-12-31

Phase I

Not yet recruiting
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
  • Condition/Disease

    Neoplasms

  • Test Drug

    Injectable

Participate Sites
6Sites

Recruiting6Sites

2020-12-01 - 2027-12-31

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-03-18 - 2024-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2025-06-01 - 2028-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-01-01 - 2028-01-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

2024-06-01 - 2027-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2021-11-01 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2022-08-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites